Rivaroxaban For Suspension shortage
Rivaroxaban For Suspension is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Oct 4, 2026.
Janssen Pharmaceuticals is stopping its rivaroxaban for suspension, and this change may be permanent. The same 155 mg suspension is still listed by Ascend Laboratories as an available source.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Rivaroxaban For Suspension. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 18, 2026Currently in shortage1 of 1 product affected.
-
Sep 18, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Janssen Pharmaceuticals 📞 800-526-7736 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Xarelto, For Suspension, 155 mg (NDC 50458-575-01) | — | — | Business Decision | — |
These rows are manufacturer reports to the FDA for Rivaroxaban For Suspension — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Rivaroxaban For Suspension? options further down this page.
Why is Rivaroxaban For Suspension in shortage?
Janssen Pharmaceuticals has reported to the FDA that they are permanently stopping the production of Xarelto (rivaroxaban) for suspension, 155 mg (the oral liquid/granule form). The reason they gave is simply a "business decision," which means the company chose to discontinue this specific product for internal business reasons — they didn't share any further public explanation beyond that.
It's worth knowing that this report covers only this particular product from Janssen — specifically that 155 mg suspension package. No recovery or restart is expected, as this is a planned discontinuation rather than a temporary shortage.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Rivaroxaban For Suspension, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Rivaroxaban For Suspension?
Rivaroxaban For Suspension is currently on the FDA shortage list, and I want to walk you through what that means for you.
The only strength on this record, 155 mg, has no available source right now. This product is also listed as to be discontinued, which means this particular supply problem may be permanent rather than temporary. The reason reported by the manufacturer, Janssen (maker of Xarelto For Suspension), is a business decision rather than a manufacturing or quality issue. Because this record covers a single maker, that does not mean the medicine is gone from every source — one other company still shows the same medicine on the market.
Here is what I suggest, in order:
- Do not stop, skip, or change this medicine on your own — this is a blood-thinning medicine, and steady dosing matters.
- Ask your pharmacy whether they can source the same medicine from another maker; our records show rivaroxaban 155 mg for suspension from Ascend Laboratories, though it may not be in local stock.
- Because this product is being discontinued, plan to talk with your prescriber or pharmacist soon about a suitable path forward.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is general, national information and may not match your pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Rivaroxaban For Suspension?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Rivaroxaban For Suspension is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Rivaroxaban | RIVAROXABAN 155 mg/1 | Granule, For Suspension · Oral | Ascend Laboratories, LLC | 67877-0882-71 |
Alternative dosage forms of Rivaroxaban For Suspension
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Rivaroxaban 155 mg | Ascend | 1 granule | $1.789 | AB | Availability likely |
| rivaroxaban granule 155 mg | Lupin | 1 bottle | $1.789 | AB | Availability likely |
| Xarelto 155 mg | Janssen | 1 granule | $3.774 | AB | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Rivaroxaban For Suspension — that fall in the same broad treatment class (direct factor xa inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other hematology shortages
Rivaroxaban For Suspension shortage FAQs
Is Rivaroxaban For Suspension in shortage?
Which products are affected?
When will Rivaroxaban For Suspension be available again?
Can I still get Rivaroxaban For Suspension somewhere?
What should I do if I take Rivaroxaban For Suspension?
Still have a question about the Rivaroxaban For Suspension shortage?
Ask a pharmacist about this shortage →View Rivaroxaban For Suspension on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.